<DOC>
	<DOCNO>NCT01680796</DOCNO>
	<brief_summary>This open-label phase I study dovitinib give combination bortezomib dexamethasone . Dovitinib dose escalation plan order determine maximum tolerate dose give combination .</brief_summary>
	<brief_title>Dovitinib Combined With Bortezomib Dexamethasone Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis multiple myeloma Karnofsky performance status ≥ 70 Age ≥ 18 year old Evidence relapse refractory disease document prior treatment history Have receive least 1 , 3 , prior treatment regimens multiple myeloma include chemotherapy , autologous stem cell transplantation , immunotherapy , investigational agent . Prior allogeneic stem cell transplant prior therapy bortezomib ( evidence disease resistance bortezomib ) permit . Last dose chemotherapy le 4 week prior receipt study medication recover side effect therapy Last dose biological therapy , antibody , investigational agent , less 4 week prior receipt study medication Subjects must follow laboratory value : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ( Hgb ) &gt; 9 g/dL Serum total bilirubin : ≤ 1.5 x ULN ALT AST ≤ 3.0 x ULN Serum creatinine ≤ 1.5 x ULN Willing able undergo bone marrow aspirate per protocol , with/without bone marrow biopsy accord study center 's practice . Life expectancy ≥ 12 week All subject ( male female ) child bear potential must agree use adequate contraceptive method . Negative serum pregnancy test ( ≤ 72 hour prior first dose dovitinib ) woman childbearing potential Subjects give write informed consent obtain accord local guideline Subjects CNS ( central nervous system ) disease Subjects another primary malignancy within 3 year prior start study drug , exception adequately treat insitu carcinoma uterine cervix , skin cancer Subjects receive last administration anticancer therapy include chemotherapy , immunotherapy , hormonal therapy monoclonal antibody ( exclude nitrosurea , mitomycinC , target therapy radiation ) ≤ 4 week prior start study drug , recover side effect therapy Subjects radiotherapy ≤ 4 week prior start study drug , ≤ 2 week prior start study drug case localize radiotherapy ( e.g . analgesic purpose lytic lesion risk fracture ) , recover radiotherapy toxicity Subjects undergone major surgery ( e.g . intrathoracic , intraabdominal intrapelvic ) , open biopsy significant traumatic injury ≤ 4 week prior start study drug , subject minor procedure , percutaneous biopsy placement vascular access device ≤ 1 week prior start study drug , recover side effect procedure injury Subjects follow concurrent severe and/or uncontrolled medical condition could compromise participation study : Impaired cardiac function clinically significant cardiac disease , include follow : 1 . History presence serious uncontrolled ventricular arrhythmias 2 . Clinically significant rest bradycardia 3 . LVEF assess 2D echocardiogram ( ECHO ) &lt; 50 % low limit normal ( whichever high ) multiple gated acquisition scan ( MUGA ) &lt; 45 % low limit normal ( whichever high ) . 4 . Any follow within 6 month prior start study drug : myocardial infarction ( MI ) , severe/unstable angina , Coronary Artery Bypass Graft ( CABG ) , Congestive Heart Failure ( CHF ) , Cerebrovascular Accident ( CVA ) , Transient Ischemic Attack ( TIA ) , Pulmonary Embolism ( PE ) 5 . Uncontrolled hypertension define SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg , without antihypertensive medication ( ) , Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption dovitinib ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) , Cirrhosis , chronic active hepatitis chronic persistent hepatitis , Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) , Subjects currently receive anticoagulation treatment therapeutic dos warfarin , Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g . active uncontrolled infection , uncontrolled diabetes ) could cause unacceptable safety risk compromise compliance protocol Pregnant breastfeed woman Women childbearing potential , biologically able conceive , willing employ two form highly effective contraception Fertile male willing use contraception Subject know hypersensitivity bortezomib , know Grade ≥ 2 bortezomibrelated neuropathy Subjects unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>